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ABSTRACT
Human cytomegalovirus is a ubiquitous pathogen with protean clinical manifestations. After initial
infection, the virus remains in a persistent state in the host. Immunity plays a pivotal role in
counteracting its virulence, albeit intermittent virus shedding occurs in immunocompetent individuals.
Should deﬁciencies in immunity occur, e.g., as a consequence of AIDS or iatrogenic immunosuppres-
sion, then virus replication and subsequent pathogenic manifestations ensue. In the oral and maxillo-
facial region, the virus causes a wide variety of diseases, mainly atypical chronic ulcerations and
sialadenitis. These morbidities are rarely reported and sometimes cause signiﬁcant problems for
clinicians.
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Human cytomegalovirus (HCMV) is an omni-
present pathogen, with a seroprevalence among
adults of 50–100%. Seropositivity against HCMV
reaches 50–80% in heterosexual individuals who
are seronegative for human immunodeﬁciency
virus (HIV), whereas homosexual HIV-seroposi-
tive males are almost always seropositive for
HCMV [1]. Seroconversion is also prominent
among individuals with poor socio-economic
status and ⁄ or in developing countries [2]. Body
ﬂuids or bone marrow ⁄ solid grafts are the means
of HCMV transmission. The primary infection is
usually of no clinical importance, unless it
involves a neonate or an immunosuppressed
individual [3]. Given that the host immune
system cannot eliminate HCMV, a persistent
latent infection follows. Although the virus is
mainly harboured by cells of myeloid lineage,
HCMV can promiscuously affect several different
cell types [4]. During latency, viral protein syn-
thesis is repressed in an effort to evade the
immune system, although some virus ‘leakage’
can be detected. Consequently, equilibrium is
established between the virus and the host.
Should the host become stressed, virus reactiva-
tion and shedding ensue [4].
In terms of pathology, HCMV is a major
pathogen that causes infections of neonates [4].
It also complicates organ allografts (especially
cardiac transplantation) and immunosuppressive
post-transplant therapy, and potentially causes
serious morbidity or mortality in patients receiv-
ing chemotherapy for cancer or collagen disease,
or in individuals suffering from AIDS, partic-
ularly if at an advanced stage [2,5,6]. It also plays
a pivotal role in atherosclerosis formation and
restenosis following coronary angioplasty [3].
HCMV is also responsible for a variety of other
diseases, ranging from an asymptomatic, sub-clin-
ical infection to an infectious mononucleosis (in
contrast to Epstein–Barr virus, HCMV rarely
causes tonsillo-pharyngitis or splenomegaly) in
otherwise healthy individuals [4]. In the context
of oral and maxillo-facial pathology, HCMV
causes mainly persistent, atypical oral mucosal
ulcers and major salivary gland infections, with or
without concomitant alterations in salivary ﬂow,
which are mainly secondary to profound immu-
nosuppression [6,7]. Rare and diverse manifesta-
tions of HCMV infection, e.g., gingival
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hyperplasia, gingivitis, periodontitis, osteomyeli-
tis of the jaw, sinusitis, hyperplasia of the oral
mucosa, and concurrent infection in Kaposi’s
sarcoma and recurrent apthous stomatitis, have
also been reported [2,7–9].
Oral ulcerations (attributed to HCMV, individu-
ally or synergically with other herpes viruses,
Histoplasma capsulatum, or even mycobacteria)
occur predominantly in conjunction with immu-
nosuppression [10–12]. Such ulcerations show
diversity in terms of clinical appearance, duration
(range l2–21 weeks) and localisation. Any oroph-
arygeal site can be involved, but ulcerations of the
hard–soft palate are the most prevalent [1,2,5].
Such lesions usually present as long-lasting, solit-
ary or numerous, painful or painless, medium-
sized, shallow ulcerations. Their base can be
covered by a yellow slough or pseudomembrane,
and the margins can be rolled, elevated, with
induration or devoid of induration [1,2,5,7,10].
Cervical lymphadenitis and pyrexia are seen
inconsistently. Therefore, HCMV-associated ulcer-
ations are non-speciﬁc, and the differential diag-
nosis includes various nosological entities [11].
Indeed, in some cases, the clinical appearance is
misleading, resulting in treatment failure and a
resulting biopsy [8].
Pathogenetically, endothelial infection is alle-
gedly the instigating factor for the development of
epithelial ulceration (as found in similar cutane-
ous and gastrointestinal lesions), unless other
infectious agents with epithelial tropism are
identiﬁed. It seems that small blood vessels are
obstructed, rendering the tissue ischaemic so that
an ulcer ensues [2,7]. In addition, HCMV can
cause parotitis in neonates. The virus remains
active during the ﬁrst year of life in 15–50% of
infants, but then remains in a dormant state in
salivary gland cells [6]. During this period,
HCMV parotitis could be a cause of sudden
infant death syndrome, since the immune system
is under-developed, as indicated by post-mortem
studies conducted in children [13]. However,
these ﬁndings are contentious, since a massive
virus reactivation is known to occur upon death
(J. Sinclair, personal communication).
In adults, local virus reactivation usually pre-
sents in the form of sialadenitis or symptoms of
salivary dysfunction following immunosuppres-
sion [6]. In this context, Greenberg et al. [6] found
that local HCMV reactivation is responsible for
xerostomia, with or without the salivary enlarge-
ment encountered in AIDS patients, affecting
primarily sub-mandibular and sub-lingual or
parotid glands. In such cases, the degree of
HCMV-induced sialadentitis and ⁄ or xerostomia
was commensurate with the HIV load, and was
inversely proportional to the CD4+ cell count. In
cases where the CD4 count was >220 cells ⁄mm3,
salivary enlargement was attributed to lympho-
cyte inﬁltration in the salivary parenchyma. Such
tumefaction could even mimic a tumour [6,14].
Overall, it can be concluded that HCMV causes
protean clinical manifestations, albeit infre-
quently, in the oral and maxillo-facial region,
ranging from non-speciﬁc ulceration and sialade-
nitis, to lesions such as periodontitis and sinusitis.
Epidemiologically, HCMV oral and maxillo-
facial infections have increased dramatically dur-
ing the last three decades. Almost all HCMV oral
and maxillo-facial infections now occur in patients
with chronic HIV infection, with a handful of cases
involving transplantations, malignancy and
immunosuppressive treatment (in most of these
cases, the CD4 count was <100 cells ⁄mm3) [2,5,6].
With HIV-infected patients, particularly when the
CD4 count is <100 cells ⁄mm3, HCMV reactivation
takes place. HIV patients harbour multiple HCMV
strains, and compartmentalisation of these strains
occurs [15]. Such strain mixtures, along with
recombination events and viral polymorphism,
confer evolutionary advantages in terms of viru-
lence, drug resistance and tropism [15].HCMValso
promotesHIV provirus activation, or HIV tropism,
through the expression of glycoprotein US28
(which mimics the CXCR4 and CCR5 chemokine
receptors), cytokine release, and up-regulation of
the CD4 receptor when both viruses coexist in the
same or bystander cells [16].
In terms of aetiopathogenesis, HCMV lesions
generally result from reactivation of a latent virus
or re-infection by another strain (or recombina-
tion), and, less frequently, from a primary infec-
tion. Several different scenarios are possible with
respect to the source of the virus. First, endothe-
lium and ductal or mucosal epithelia could host
latent HCMV, with immunosuppression resulting
in its reactivation; indeed, periodontal tissues
have recently been implicated as the source of
HCMV salivary shedding in patients with perio-
dontitis [17]. Second, HCMV could colonise
endothelial cells during the course of a blood-
borne infection, since detection of HCMV may
occur in parallel with viraemia; moreover, in the
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event of disseminated HCMV disease, virus
spread is facilitated by means of detached endo-
thelial cells from remote infected sites or engage-
ment-tethering of infected peripheral blood cells
to endothelium, through an intercellular adhesion
molecule-1 (endothelial cell) and a leukocyte
function-associated molecule-1 (polymorphonu-
clear leukocyte) or membrane-activated complex-
1 (monocyte) interaction [18]. In addition, HCMV
induces a monocyte-to-macrophage differenti-
ation, thus facilitating virus dissemination from
blood to peripheral tissues [19]. Third, the pres-
ence of HCMV could result from auto-inoculation
by the shedding of HCMV through saliva (or even
semen) [20]. Finally, dendritic cells could form a
true reservoir of virus [21] (J. Sinclair, personal
communication).
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